Non-adherence to cardiovascular medications

European Heart Journal

Volumn 35, Issue 46, 2014, Pages 3267-3276

  Kolandaivelu, Kumaran ^a,b   Leiden, Benjamin B ^a   O'Gara, Patrick T ^b   Bhatt, Deepak L ^b  

^a USA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Coronary heart disease; Non adherence

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; CAUSE OF DEATH; EVIDENCE BASED PRACTICE; HAZARD RATIO; HUMAN; ISCHEMIC HEART DISEASE; MEDICATION COMPLIANCE; MORTALITY; OUTCOME ASSESSMENT; PANDEMIC; PATIENT CARE; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SECONDARY PREVENTION; CORONARY DISEASE; HEALTH; PATIENT EDUCATION; PATIENT SATISFACTION; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

CARDIOVASCULAR AGENTS; CORONARY DISEASE; GLOBAL HEALTH; HUMANS; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84924059881     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu364     Document Type: Review

References (96)

1. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006; 368: 679-686.
2. Smith SC Jr, Zheng ZJ. The impending cardiovascular pandemic in China. Circ Cardiovasc Qual Outcomes 2010; 3: 226-227.
3. WHO. Cardiovascular Diseases, Fact Sheet. Geneva: WHO; 2009.
4. Choudhry NK. Improving the pathway from cardiovascular medication prescribing to longer-Term adherence: new results about old issues. Circ Cardiovasc Qual Outcomes 2010; 3: 223-225.
5. Rodgers A. A cure for cardiovascular disease? Combination treatment has enormous potential, especially in developing countries. BMJ 2003; 326: 1407-1408.
6. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119: 3028-3035.
7. Baroletti S, DellOrfano H. Medication adherence in cardiovascular disease. Circulation 2010; 121: 1455-1458.
8. Smith SCJr. Evidence-based medicine: making the grade: miles to go beforewesleep. Circulation 2006; 113: 178-179.
9. Al-Lawati S. A Report on Patient Non-Adherence in Ireland. Dublin: Pfizer; 2014.
10. OConnor PJ. Improving medication adherence: challenges for physicians, payers, and policy makers. Arch Intern Med 2006; 166: 1802-1804.
11. Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation 2008; 117: 1261-1268.
12. Sabate Eea. Adherence to Long-Term Therapies: Policy for Action. . Geneva: World Health Organization; 2001.
13. Rodriguez FCC, Steg PG, Kumbhani DJ, Goto S, Smith SC, Eagle KA, Ohman EM, Umez-Eronini AA, Hoffman E, Bhatt DL, REACH Registry Investigators. Predictors of long-Term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol 2013; 36: 721-727.
14. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 1842-1847.
15. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008; 117: 1028-1036.
16. Melloni C, Alexander KP, Ou FS, LaPointe NM, Roe MT, Newby LK, Baloch K, Ho PM, Rumsfeld JS, Peterson ED. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol 2009; 104: 175-181.
17. Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010; 41: 397-401.
18. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin inmenwith hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
19. 4S-Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
20. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462-467.
21. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-Term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113: 203-212.
22. Hauptman PJ. Medication adherence in heart failure. Heart Fail Rev 2008; 13: 99-106.
23. Leventhal MJ, Riegel B, Carlson B, De Geest S. Negotiating compliance in heart failure: remaining issues and questions. Eur J Cardiovasc Nurs 2005; 4: 298-307.
24. Osterberg L, Blaschke T. Adherence to medication.NEngl JMed2005; 353: 487-497.
25. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK. Use of secondary prevention drugs for cardiovascular disease in the community in highincome, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378: 1231-1243.
26. Solomon MD, Majumdar SR. Primary non-Adherence of medications: lifting the veil on prescription-filling behaviors. J Gen Intern Med 2010; 25: 280-281.
27. Schroeder KFT, Emrahim S, Peters T. Adherence to long-Term therapies: recent WHO report provides some answers but poses even more questions. J Clin Epidemiol 2004; 57: 2-3.
28. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 345-356.
29. Ernst ME MM. Use of diuretics in patients with hypertension.NEngl J Med 2009; 361: 2153-2164.
30. Leenen FH FA, Notman G, Tanner J. Persistence of anti-hypertensive effect after missed doses of calcium antagonist with long (amlodipine) vs. short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41: 83-88.
31. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4-9.
32. Vrijens B, Claeys MJ, Legrand V, Vandendriessche E, Van deWerf F. Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Br J Clin Pharmacol 2014; 77: 746-755.
33. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-459.
34. Yusuf SZF, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
35. Ho PM, Tsai TT, Wang TY, Shetterly SM, Clarke CL, Go AS, Sedrakyan A, Rumsfeld JS, Peterson ED, Magid DJ. Adverse events after stopping clopidogrel in post-Acute coronary syndrome patients: Insights from a large integrated healthcare delivery system. Circ Cardiovasc Qual Outcomes 2010; 3: 303-308.
36. Houston MC, Hodge R. Beta-Adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988; 116(2 Pt 1): 515-523.
37. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidencebased pharmacotherapy and long-Term mortality after acute myocardial infarction. JAMA 2007; 297: 177-186.
38. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-360.
39. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
40. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
41. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803-2809.
42. Ho PM, Tsai TT, Maddox TM, Powers JD, Carroll NM, Jackevicius C, Go AS, Margolis KL, DeFor TA, Rumsfeld JS, Magid DJ. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care. Circ Cardiovasc Qual Outcomes 2010; 3: 261-266.
43. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Hoffman E, Goto S, Ohman EM, Bhatt DL. Adherence to secondary prevention medications and fouryear outcomes in outpatients with atherosclerosis. Am J Med 2013; 126: 693-700 e691.
44. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, DAgostino R, Liau CS, Mas JL, Rother J, Smith SC Jr, Salette G, Contant CF, Massaro JM, Steg PG. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010; 304: 1350-1357.
45. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130.
46. Collet JP, Montalescot G, Steg PG, Steinhubl SR, Fox KA, Hu TF, Johnston SC, Hamm CW, Bhatt DL, Topol EJ. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis 2009; 102: 485-496.
47. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980; 303: 1038-1041.
48. Granger BB SK, Ekman I, Granger CB, Olofsson B, McMurray JJ, Yusuf S, Michelson EL, Pfeffer MA. CHARM investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: doubleblind, randomised, controlled clinical trial. Lancet 2005; 366: 2005-2011.
49. White HD. Adherence and outcomes: its more than taking the pills. Lancet 2005; 366: 1989-1991.
50. Ho PM MD, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008; 155: 772-779.
51. Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013; 128: 1055-1065.
52. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 2: CD000011.
53. Fried TR, Tinetti ME, Towle V, OLeary JR, Iannone L. Effects of benefits and harmson older persons willingness to take medication for primary cardiovascular prevention. Arch Intern Med 2011; 171: 923-928.
54. Serebruany V, Rao SV, Silva MA, Donovan JL, Kannan AO, Makarov L, Goto S, Atar D. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2009; 2: 227-235.
55. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis.N Engl J Med 2007; 357: 2078-2081.
56. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
57. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, Grobbee DE, Bots ML, Reddy KS, Cidambi R, Bompoint S, Billot L, Rodgers A. Effects of a fixed-dose combination strategyon adherence and risk factors in patients with or at high risk ofCVD: the UMPIRE randomized clinical trial. JAMA 2013; 310: 918-929.
58. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, Sigamani A, Mohan V, Gupta R, Thomas N. Effects of a polypill (Polycap) on risk factors in middle-Aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373: 1341-1351.
59. Ruxin J, Paluzzi JE, Wilson PA, Tozan Y, Kruk M, Teklehaimanot A. Emerging consensus in HIV/AIDS, malaria, tuberculosis, and access to essential medicines. Lancet 2005; 365: 618-621.
60. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009; 119: 390-397.
61. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care 2006; 12: 678-683.
62. Hsu J, Price M, Huang J, Brand R, Fung V, Hui R, Fireman B, Newhouse JP, Selby JV. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 2006; 354: 2349-2359.
63. Oates DJ, Paasche-Orlow MK. Health literacy: communication strategies to improve patient comprehension of cardiovascular health. Circulation 2009; 119: 1049-1051.
64. Kumbhani DJ, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Pan W, Schwamm LH, Bhatt DL. Predictors of adherence to performance measures in patients with acutemyocardial infarction.AmJMed 2013; 126: 74 e71-e79.
65. Gukathasan N, Witzenbichler B, Weisz G, Henry T, Colombo A, Baber U, Chieffo A, Gibson CM, Vadde R, Bharathi P, Sartori S, Kini A, Iakovou A, Krucoff M, Steg P, Mehran R. Impact of gender of patterns of dual antiplatelet therapy cessation and nonadherence: one-year results from the patterns of non-Adherence to anti-platelet regimens in stented patients (PARIS), an observational single-Arm study. J Am Coll Cardiol 2013; 61: E1531.
66. Glassman AH, OConnor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, McLvor M. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-709.
67. Kronish IM, Edmondson D, Goldfinger JZ, Fei K, Horowitz CR. Posttraumatic stress disorder and adherence to medications in survivors of strokes and transient ischemic attacks. Stroke 2012; 43: 2192-2197.
68. Williams L, OConnor RC, Grubb N, OCarroll R. Type D personality predicts poor medication adherence inmyocardial infarction patients. Psychol Health 2011; 26: 703-712.
69. Bokhour BG BD, Long JA, Kressin NR. How do providers assess antihypertensive medication adherence in medical encounters? J Gen Intern Med 2006; 21: 577-583.
70. Olson DP WD. Communication discrepancies between physicians and hospitalized patients. Arch Intern Med 2010; 170: 1302-1307.
71. Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital-based medication reconciliation practices: a systematic review. Arch Intern Med 2012; 172: 1057-1069.
72. Bell CM BS, Gunraj N, Huo C, Bierman AS, Scales DC, Bajcar J, Zwarenstein M, Urbach DR. Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. JAMA 2011; 306: 840-847.
73. Nguyen TM, Caze AL, Cottrell N. What are validated self-report adherence scales really measuring? A systematic review. Br J Clin Pharmacol 2014; 77: 427-445.
74. Son YJ, Kim HG, Kim EH, Choi S, Lee SK. Application of support vector machine for prediction of medication adherence in heart failure patients. Healthc Inform Res 2010; 16: 253-259.
75. Bourdes V, Ferrieres J, Amar J, Amelineau E, Bonnevay S, Berlion M, Danchin N. Prediction of persistence of combined evidence-based cardiovascular medications in patients with acute coronary syndrome after hospital discharge using neural networks. Med Biol Eng Comput 2011; 49: 947-955.
76. Kelly LF. Payers see predictive modeling, tailored interventions as next wave in adherence. Drug Benefit News 2012; 13: 1-5.
77. Zedler BK, Kakad P, Colilla S, Murrelle L, Shah NR. Does packaging with a calendar feature improve adherence to self-Administered medication for long-Term use? A systematic review. Clin Ther 2011; 33: 62-73.
78. Misono AS, Cutrona SL, Choudhry NK, Fischer MA, Stedman MR, Liberman JN, Brennan TA, Jain SH, Shrank WH. Healthcare information technology interventions to improve cardiovascular and diabetes medication adherence. Am J Manag Care 2010; 16(12 Suppl HIT): SP82-SP92.
79. Derose SF, Green K, Marrett E, Tunceli K, Cheetham TC, Chiu VY, Harrison TN, Reynolds K, Vansomphone SS, Scott RD. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med 2013; 173: 38-43.
80. Carter BL, Ardery G, Dawson JD, James PA, Bergus GR, Doucette WR, Chrischilles EA, Franciscus CL, Xu Y. Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med 2009; 169: 1996-2002.
81. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006; 296: 2563-2571.
82. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, Reisman L, Fernandes J, Spettell C, Lee JL, Levin R, Brennan T, Shrank WH. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011; 365: 2088-2097.
83. Danchin NNA, Tuppin P, De Peretti C, Weill A, Ricordeau P, Allemand H. Impact of free universal medical coverage on medical care and outcomes in low-income patients hospitalized for acute myocardial infarction: an analysis from the French National Health Insurance System. Circ Cardiovasc Qual Outcomes 2011; 4: 619-625.
84. Volpp KG, Loewenstein G, Troxel AB, Doshi J, Price M, Laskin M, Kimmel SE. Atest of financial incentives to improve warfarin adherence. BMC Health Serv Res 2008; 8: 272.
85. Clyne W, White S, McLachlan S. Developing consensus-based policy solutions for medicines adherence for Europe: a Delphi study. BMC Health Serv Res 2012; 12: 425.
86. Schnipper JL HC, Ndumele CD, Liang CL, Carty MG, Karson AS, Bhan I, Coley CM, Poon E, Turchin A, Labonville SA, Diedrichsen EK, Lipsitz S, Broverman CA, McCarthy P, Gandhi TK. Effect of an electronic medication reconciliation application and process redesign on potential adverse drug events: a cluster-randomized trial. Arch Intern Med 2009; 169: 771-780.
87. Boockvar KS BS, Kugler A, Livote E, Mergenhagen KA, Nebeker JR, Signor D, Sung S, Yeh J. Effect of admission medication reconciliation on adverse drug events from admission medication changes. Arch Intern Med 2011; 171: 860-861.
88. Karapinar-Carkit FBS, Zoer J, Smit HJ, Egberts AC, van den Bernt PM. Effect of medication reconciliation with and without patient counseling on the number of pharmaceutical interventions among patients discharged from the hospital. Ann Pharmacother 2009; 43: 1001-1010.
89. Witticke DSH, Lohmann K, Send AF, Haefeli WE. Opportunities to reduce medication regimen complexity: a retrospective analysis of patients discharged from a university hospital in Germany. Drug Saf 2013; 36: 31-41.
90. Schiff GD, Galanter WL, Duhig J, Lodolce AE, Koronkowski MJ, Lambert BL. Principles of conservative prescribing. Arch Intern Med 2011; 171: 1433-1440.
91. Peterson ED, Albert NM, Amin A, Patterson JH, Fonarow GC. Implementing critical pathways and a multidisciplinary team approach to cardiovascular disease management. Am J Cardiol 2008; 102: 47G-56G.
92. Brilakis ES, Hernandez AF, Dai D, Peterson ED, Banerjee S, Fonarow GC, Cannon CP, Bhatt DL. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. Circulation 2009; 120: 560-567.
93. Gillespie U, Alassaad A, Henrohn D, Garmo H, Hammarlund-Udenaes M, Toss H, Kettis-Lindblad A, Melhus H, Morlin C. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med 2009; 169: 894-900.
94. Boswell KA, Cook CL, Burch SP, Eaddy MT, Cantrell CR. Associating medication adherence with improved outcomes: a systematic literature review.AmJ Pharm Benefits 2012; 4: e97-e108.
95. Cutler DM, Everett W. Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med 2010; 362: 1553-1555.
96. Leenen FH, Fourney A, Notman G, Tanner J. Persistence of anti-hypertensive effect after missed dosesof calcium antagonist with long (amlodipine) vs. short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41: 83-88.